Urinary Tract Infections Clinical Trial
— COLIFOXOfficial title:
Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli
Verified date | August 2017 |
Source | Central Hospital, Nancy, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background Information: Infections caused by extended-spectrum β-lactamase (ESBL)-producing
Escherichia coli are becoming increasingly common owing to incorrect use of antibiotics and
cross-transmission in healthcare establishments. These give rise to major problems in
standard clinical practice: penicillins and cephalosporins cannot be used, and resistance to
the other classes of antibiotics normally used, such as fluoroquinolones or cotrimoxazole, is
very frequently observed. The current therapeutic strategy involves the use of a carbapenem,
which represents the last effective solution on an individual level. However, the growing use
thereof is contributing, collectively, to the development of resistance due to the production
of carbapenemases, which will become a major public health problem, with a potential
therapeutic dead-end. This observation is particularly worrying due to the very small number
of antibiotic agents currently in development.
Infectious disease specialists and microbiologists are thus examining alternative agents to
carbapenems in the management of infections caused by ESBL-producing E. coli. One of the
avenues which could be developed is the use of known agents, already on the market, which are
active in vitro on ESBL-producing E. coli, but which are not currently recommended for this
indication in standard practice due to the lack of conclusive studies. Cefoxitin, an
antibiotic belonging to the cephamycin group, could thus represent an alternative of
particular interest in the treatment of infections caused by ESBL-producing E. coli, and help
limit the use of carbapenems.
The implementation of a prospective, randomized, non-inferiority study on ertapenem and
cefoxitin is of the most interest from a methodological perspective. It will enable
recommendations to be drawn up, with a high level of evidence, very long-awaited in the
field.
Primary objective: To evaluate the bacteriological non-inferiority of cefoxitin versus
imipenem in the treatment of non-severe urinary tract infections (other than cystitis) caused
by ESBL-producing E. coli susceptible in vitro to cefoxitin.
Secondary objectives:
- To evaluate the clinical non-inferiority of cefoxitin versus imipenem in the treatment
of non-severe urinary tract infections (other than cystitis) caused by ESBL-producing E.
coli susceptible in vitro to cefoxitin.
- To evaluate the impact of cefoxitin and imipenem on the emergence of multiresistant
bacteria in the gut flora.
Status | Terminated |
Enrollment | 6 |
Est. completion date | December 2017 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age = 18 years - Patient admitted to any medical or surgical department in the participating centre - Documented urinary tract infection (other than cystitis), with or without bacteremia, caused by ESBL-producing E. coli susceptible in vitro to cefoxitin (minimal inhibition concentration <= 8 mg/L and /or diameter = 19 mm according to CA-SFM 2015) and resistant to fluoroquinolones and to association trimethoprim-sulfamethoxazole. An E. Coli urinary tract infection is defined according to SPILF 2014 Clarification by a leucocytury = 104/mL and clinical significant limit at 103 UFC/ml, for the men or the women. - Medical examination prior to inclusion - Informed consent signed by the patient - Patient affiliated to a French Sécurité Social regimen Exclusion Criteria: - Serious infection (severe sepsis, septic shock) - Pregnant or breast-feeding women - Chronic kidney failure (creatinine clearance < 30 ml/min) and/or dialysis - Hypersensibility to imipenem/cilastatine, to cefoxitine - Hypersensibility to another antibiotics of cephalosporine class - Hypersensibility to another antibiotics of carbapenem class - Severe hypersensibility (ex :anaphylactic reaction, or serious cutaneous reaction) to all other antibiotics from beta lactamines family (ex : penicillins, monobactam) - Treatment with ganciclovir and/or valproic acid - Infection on the urinary cathether - Empirical antibiotic therapy including an aminoglycoside - Patient being treated with antibiotic(s) for another infection - Patient participating to another interventional study - Patient not compliant according to the investigator's opinion - Patient under guardianship |
Country | Name | City | State |
---|---|---|---|
France | CHRU Nancy | Nancy |
Lead Sponsor | Collaborator |
---|---|
Central Hospital, Nancy, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Control urine culture negative | 7 days after the end of treatment | ||
Secondary | absence of fever | temperature lower than 38°C | 3 days after the beginning of study treatment | |
Secondary | presence of multiresistant bacteria in a rectal swab | 7 days after the end of treatment | ||
Secondary | Composite outcome measure consisting of resolution of clinical signs observed on diagnosis | Absence of lower back pain, and/or absence of fictional burning, and/or absence of pollakiuria, and/or dysuria, and/or gross hematuria and/or abdominal pain | 7 days after the end of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04495699 -
Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
|
||
Terminated |
NCT05254808 -
EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
|
Phase 3 | |
Completed |
NCT03680612 -
Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI
|
Phase 2 | |
Completed |
NCT03282006 -
Treating Pyelonephritis an Urosepsis With Pivmecillinam
|
Phase 4 | |
Completed |
NCT03526484 -
The Utility of Urinalysis Prior to In-Office Procedures
|
N/A | |
Completed |
NCT05397782 -
Effects of Flourish on Recurrent Urinary Tract Infection
|
N/A | |
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03687255 -
Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
|
Phase 3 | |
Recruiting |
NCT05227937 -
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
|
||
Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
Completed |
NCT03131609 -
Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
|
||
Completed |
NCT01911143 -
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
|
N/A | |
Completed |
NCT01333254 -
A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients
|
N/A | |
Terminated |
NCT00594594 -
Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury
|
Phase 1 | |
Completed |
NCT00216853 -
A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection
|
N/A | |
Completed |
NCT00787085 -
The Significance of Funguria in Hospitalized Patients
|
N/A | |
Completed |
NCT05719753 -
The Effectiveness of a Bacteriophobic Coating on Urinary Catheters
|
N/A | |
Recruiting |
NCT05415865 -
The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder
|
Phase 3 | |
Not yet recruiting |
NCT05880329 -
DIagnoSing Care hOme UTI Study
|
||
Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|